Compare Lockheed Martin Corporation (LMT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs TG Therapeutics Inc — how do they compare? Lockheed Martin Corporation trades at $508.27 (market cap $117.22B), while TG Therapeutics Inc trades at $54.83 (market cap $8.16B). The key difference: Lockheed Martin Corporation is far larger — about 14.4× TG Therapeutics Inc's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and TG Therapeutics Inc for 16 Days on average.
| LMT | TGTX | |
|---|---|---|
Market Cap | $117.22B | $8.16B |
Volume | 1,101,121 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $676.70 | $59.06 |
52-Week Low | $439.19 | $26.94 |
Typical Hold Time | 86 Days | 16 Days |
Enterprise Value | $133.96B | $8.37B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $508.18, up 1.79% with a bearish technical signal despite recent earnings beat. The defense contractor shows strong fundamentals with $75.05B revenue, 8.16% net margin, and robust cash flow of $8.56B from operations. Recent news highlights AI integration and F-35 program developments, while analyst consensus remains bullish with a $635.33 price target representing 25% upside potential.
LMT presents a compelling value opportunity with attractive valuation multiples (P/E 18.73, P/S 1.53) and 23-year dividend growth streak. Key risks include dependency on Pentagon contracts and fixed-price contract volatility. The stock's current discount to analyst targets and defensive positioning in aerospace/defense sector support long-term investment case despite near-term technical weakness.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
